Form 4: Recursion Pharma CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Recursion Pharmaceuticals CEO Christopher Gibson sold 100,000 shares of Class A Common Stock for $4.76 per share, executed under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals, Inc. (RXRX), reported transactions on September 25, 2025.
- He converted 100,000 shares of Class B Common Stock into Class A Common Stock.
- Concurrently, he sold 100,000 shares of Class A Common Stock at a price of $4.76 per share.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
- Following the reported transactions, Gibson directly beneficially owns 954,229 shares of Class A Common Stock.
- He also holds significant derivative securities, including various stock options with exercise prices ranging from $2.48 to $11.40 and expiration dates extending to 2035.
- Indirect beneficial ownership includes 386,000 shares of Class B Common Stock held by LAHWRAN-3 LLC, 388,000 shares by LAHWRAN-4 LLC, and 50,000 shares by the Gibson Family Trust, all entities where Gibson has a controlling interest.
Sentiment
Score: 5
Explanation: A neutral score. While an insider sale can be perceived negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling. The CEO retains substantial ownership, indicating continued alignment with company performance.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, rather than reactive, transaction, which can mitigate concerns about opportunistic selling.
- The CEO retains substantial direct and indirect beneficial ownership, including a large number of stock options, aligning his interests with long-term shareholder value.
Negatives
- An insider sale by the CEO, even if planned, can sometimes be perceived negatively by the market as it reduces direct ownership.
Future Outlook
The filing does not provide specific forward-looking statements or guidance beyond the pre-scheduled nature of the insider transaction and the vesting schedules of existing stock options.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide information to analyze broader industry trends or competitor activities. Insider sales are common across all industries, particularly when executed under pre-arranged 10b5-1 plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Adoption | The reporting person adopted a Rule 10b5-1 trading plan on May 12, 2025, which governed the reported sale of Class A Common Stock. | 2025-05-12 | This plan allows insiders to sell shares at pre-determined times or prices, providing an affirmative defense against insider trading allegations and promoting transparency. |
Related Party Transactions
- Indirect beneficial ownership of Class B Common Stock through LAHWRAN-3 LLC, of which the Reporting Person is a member and manager.
- Indirect beneficial ownership of Class B Common Stock through LAHWRAN-4 LLC, of which the Reporting Person is a member and manager.
- Indirect beneficial ownership of Class B Common Stock through the Gibson Family Trust, of which the Reporting Person serves as Trustee.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO could lead to short-term negative sentiment, though the 10b5-1 plan mitigates concerns about opportunistic selling. The CEO's continued substantial ownership maintains alignment with shareholder interests.
Next Steps
- Continued monthly vesting of various stock options held by the CEO, as per their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 2021-01-31 | Vesting start date for stock option (originally 1,500,000 shares) with exercise price $2.48. |
| 2022-02-04 | Vesting start date for stock option (originally 416,350 shares) with exercise price $11.40. |
| 2023-03-01 | Vesting start date for stock option with exercise price $8.55. |
| 2024-03-01 | Vesting start date for stock option with exercise price $10.09. |
| 2025-03-01 | Vesting start date for stock option with exercise price $7.25. |
| 2025-05-12 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-09-25 | Date of reported transactions (conversion and sale of Class A Common Stock). |
| 2025-09-26 | Signature date of the filing. |
| 2030-12-30 | Expiration date for stock option with exercise price $2.48. |
| 2032-02-04 | Expiration date for stock option with exercise price $11.40. |
| 2033-02-01 | Expiration date for stock option with exercise price $8.55. |
| 2034-02-09 | Expiration date for stock option with exercise price $10.09. |
| 2035-02-03 | Expiration date for stock option with exercise price $7.25. |
Recommendation
holdThe filing reports a pre-scheduled insider sale by the CEO under a Rule 10b5-1 plan, which is a routine event and does not inherently signal a change in the company's fundamental outlook. While a sale by a key executive can sometimes cause concern, the planned nature of the transaction and the CEO's continued significant direct and indirect holdings suggest no immediate reason to alter an investment position based solely on this filing. Investors should consider broader company performance and market conditions.
Keywords
Recursion Pharmaceuticals, RXRX, Christopher Gibson, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.